Completed PHASE2 INTERVENTIONAL 14-arm NCT01464827

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 With Ritonavir (ABT-450/r) in Combination With ABT-267 and/or ABT-333 With and Without Ribavirin (RBV) for 8, 12 or 24 Weeks in Treatment-Naïve and Null Responder Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Sponsor: AbbVie (prior sponsor, Abbott)

Conditions Chronic Hepatitis C Hepatitis C (HCV) Hepatitis C Genotype 1

Interventions ABT-267 ABT-333 ABT-450 Ribavirin Ritonavir

Updated 7 times since 2017 Last updated: Apr 2, 2015 Started: Oct 31, 2011 Primary completion: Mar 31, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01464827, this PHASE2 trial focuses on Chronic Hepatitis C and Hepatitis C (HCV) and remains completed. Sponsored by AbbVie (prior sponsor, Abbott), it has been updated 7 times since 2011, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie (prior sponsor, Abbott)

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Ann Arbor, United States , Annandale, United States , Annapolis, United States , Auckland, New Zealand , Aurora, United States , Bakersfield, United States , Baltimore, United States , Barcelona, Spain , Berlin, Germany and 75 more locations